Drugs / IBI3026
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07327632 | Jan → Dec 2026 expected | cancer | Innovent Biologics Technology Limited (Shanghai R&D Center) | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-04-28 | Innovent Biologics (Suzhou) Co. Ltd. | Results 2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs innoventbio.com ↗
IBI3026 is a bispecific immune agonist targeting PD-1 and IL-12 receptor, designed to improve safety profile by reducing IL-12 activity while enabling tumor-targeted activation through PD-1+ T cell enrichment |
| 2025-03-27 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting innoventbio.com ↗
IBI3026, a first-in-class anti-PD-1/IL-12 fusion protein, demonstrates the potential to be a new immuno-oncology therapy by releasing the break in immune response and strongly activating T and NK cells in the tumor microenvironment |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-28 | Innovent Biologics (Suzhou) Co. Ltd. | 2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs innoventbio.com ↗ |
| 2025-03-27 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting innoventbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3026 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07327632 ↗ |
| Target | PDCD1 | “Recombinant anti-programmed death receptor-1 (PD-1) antibody fused with interleukin-12 (IL-12) bispecific molecule injection” NCT07327632 ↗ |